Prognostic significance of CD109 expression in patients with ovarian epithelial cancer

Abstract

Background: Ovarian epithelial cancer (OEC) is the second-most common gynecologic malignancy. CD109 expression is elevated in human tumor cell lines and carcinomas. A previous study showed that CD109 expression is elevated in human tumor cell lines and CD109 plays a role in cancer progression. Therefore, this study aimed to determine whether CD109 is expressed in OEC and can be useful in predicting the prognosis. Methods: Immunohistochemical staining for CD109 and reverse transcription-quantitative polymerase chain reaction was performed. Then we compared CD109 expression and chemoresistance, overall survival, and recurrence-free survival of OEC patients. Chemoresistance was evaluated by dividing into good-response group and poor-response group by the time to recurrence after chemotherapy. Results: CD109 expression was associated with overall survival (p=.020), but not recurrence-free survival (p=.290). CD109 expression was not an independent risk factor for overall survival due to its reliability (hazard ratio, 1.58; p=.160; 95% confidence interval, 0.82 to 3.05), although we found that CD109 positivity was related to chemoresistance. The poor-response group showed higher rates of CD109 expression than the good-response group (93.8% vs 66.7%, p=.047). Also, the CD109 mRNA expression level was 2.88 times higher in the poor-response group as compared to the good-response group (p=.001). Conclusions: Examining the CD109 expression in patients with OEC may be helpful in predicting survival and chemotherapeutic effect.